In utero diethylstilbestrol (DES) exposure is a risk factor for rare development of vaginal and cervical cancer and may potentially be a risk factor for breast cancer. Mammography use in this population is relatively unknown; therefore, this study aims to determine if in utero DES exposure is associated with the frequency of mammography screening examinations while considering demographic and clinical factors.
Methods:
Using combined DES cohort questionnaire data, self-reported mammography screening over the past 5 years (2001–2006) was analyzed in women aged ≥45 years. Binary logistic regression assessed if DES exposure was associated with mammography use after adjustment for benign breast disease (BBD), previous cancer diagnosis, and whether insurance access influenced screening use.
Results:
Overall, the frequency of mammography examinations was similar for both DES-exposed and unexposed women. DES-exposed (n=2986) and unexposed women (n=1397) over the age of 44 reported receiving ≥3 mammography examinations in the past 5 years (73.8% and 74.0%, respectively). After adjustment, DES exposure was not associated with ≥3 mammograms in the past 5 years compared to ≤2 examinations (odds ratio [OR] 1.00, 95% confidence interval [CI] 0.86-1.17), p=0.99).
Conclusions:
In utero DES exposure was not associated with mammography use, nor was health insurance status or a BBD or cancer diagnosis. Because of the potential elevated risk for breast cancer in women exposed prenatally to DES, continued monitoring of standard mammography recommendations is recommended for this group, which is predominantly over the age of 45.
Get full access to this article
View all access options for this article.
References
1.
HerbstAL, UlfelderH, PoskanzerDC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med, 1971; 284:878–881.
2.
HatchEE, PalmerJR, Titus-ErnstoffLet al.Cancer risk in women exposed to diethylstilbestrol in utero. JAMA, 1998; 280:630–634.
3.
TroisiR, HatchEE, Titus-ErnstoffLet al.Cancer risk in women prenatally exposed to diethylstilbestrol. Int J Cancer, 2007; 121:356–360.
4.
Federal Food and Drug Administration Bulletin. Diethylstilbestrol contraindicated in pregnancy. Washington, DC: U.S. Department of Health, Education, and Welfare, 1971.
5.
PalmerJR, WiseLA, HatchEEet al.Prenatal diethylstilbestrol exposure and risk of breast cancer. Cancer Epidemiol Biomarkers Prev, 2006; 15:1509–1514.
6.
HatchEE, HerbstAL, HooverRNet al.Incidence of squamous neoplasia of the cervix and vagina in women exposed prenatally to diethylstilbestrol (United States)Cancer Causes Control, 2001; 12:837–845.
7.
PalmerJR, HatchEE, RosenbergCLet al.Risk of breast cancer in women exposed to diethylstilbestrol in utero: Preliminary results (United States)Cancer Causes Control, 2002; 13:753–758.
8.
WacholderS, HartageP, PrenticeRet al.Performance of common genetic variants in breast-cancer risk models. N Eng J Med, 2010; 362:986–993.
9.
Centers for Disease Control and Prevention. Decline in breast cancer incidence—United States, 1999–2003. MMWR, 2007; 56:549–553.
10.
ElmoreJG, ArmstrongK, LehmanCD, FletcherSW. Screening for breast cancer. JAMA, 2005; 293:1245–1256.
11.
U.S. Preventive Services Task Force. Screening for breast cancer: Recommendations and rationale. Ann Intern Med, 2002; 137:344–346.
12.
RingashJ. Canadian Task Force on Preventive Health Care. Preventive health care, 2001 update: Screening mammography among women aged 40–49 years at average risk of breast cancer. Can Med Assoc J, 2001; 164:469–476.
13.
CampEA, CokerAl, TroisiRet al.Breast cancer screening in women exposed in utero to diethylstilbestrol. J Womens Health, 2009; 18:547–552.
14.
Centers for Disease Control and Prevention. Use of mammograms among women aged ≥40 years—United States, 2000–2005. MMWR, 2007; 56:49–51.
15.
PhillipsKA, KerlikowskeK, BakerLC, ChangSW, BrownML. Factors associated with women's adherence to mammography screening guidelines. Health Serv Res, 1998; 33:29–42.
16.
SwanJ, BreenN, CoatesRJ, RimerBK, LeeNC. Progress in cancer screening practices in the United States: Results from the 2000 National Interview Survey. Cancer, 2003; 97:1528–1540.
17.
SelvinE, BrettKM. Breast and cervical cancer screening: Sociodemiographic predcitors among white, black, and Hispanic women. Am J Public Health, 200; 93:618–623.
18.
JefferiesJA, RobboySJ, O'BrienPCet al.Structural anomalies of the cervix and vagina in women enrolled in the diethylstilbestrol adenosis (DESAD) project. Am J Obstet Gynecol, 1984; 148:59–66.
19.
CampEA, CokerAl, TroisiRet al.Cervical screening and general physical examination behaviors of women exposed in utero to diethylstilbestrol. J Lower Genital Tract Dis, 2008; 12:111–117.
20.
American College of Obstetricians and Gynecologists. Committee opinion: Committee on Gynecologic Practice. Diethylstilbestrol. Int J Gynecol Obstet, 1994; 44:184.
21.
MooreKG. A survey of state Medicaid policies for coverage of screening mammography and Pap smear services. Womens Health Inst, 1992; 2:40–49.
22.
GreenBB, TaplinSH. Breast cancer screening controversies. J Am Board Fam Pract, 2003; 16:233–241.
23.
RobsonM, OffitK. Management of an inherited predisposition to breast cancer. N Eng J Med, 2007; 357:154–162.
24.
Centers for Disease Control and Prevention. Vital signs: Breast cancer screening among women aged 50–74 years—United States, 2008. MMWR, 2010; 59:813–816.
25.
BlackwellDL, MartinezME, GentlemanJF. Women's compliance with public health guidelines for mammograms and Pap tests in Canada and the United States. Womens Health Issues, 2008; 18:85–99.
26.
ShinS, SchneiderHB, ColeFJ, LarongaC. Follow-up recommendations for benign breast biopsies. Breast J, 2006; 12:413–417.
27.
MiedemaB, TatemichiS. Breast and cervical cancer screening for women between 50 and 69 years of age: What prompts women to screen?Womens Health Issues, 2003; 13:180–184.
28.
AminA, ShriverCD, HenryLR, LeningtonS, PeoplesGE, StojadinovicA. Breast cancer screening compliance among young women in a free access healthcare system. J Surg Oncol, 2008; 97:20–24.
29.
KatapodiMC, LeeKA, FacioneNC, DoddMJ. Predictors of perceived breast cancer risk and the relation between received risk and breast cancer screening: A meta-analytic review. Prev Med, 2004; 38:388–402.
30.
SchuelerKM, ChuPW, Smith-BindmanR. Factors associated with mammography utilization: A systematic quantitative review of the literature. J Womens Health, 2008; 17:1477–1498.
31.
LeggJS, FauberTL, OzcanYA. The influence of previous breast cancer upon mammography utilization. Womens Health Issues, 2003; 13:62–67.
32.
AntillYC, ReynoldsJ, YoungMAet al.Screening behavior in women at increased familial risk for breast cancer. Fam Cancer, 2006; 5:359–368.
33.
HayJL, McCaulKD, MagnanRE. Does worry about breast cancer predict screening behaviors? A meta-analysis of the prospective evidence. Prev Med, 2006; 42:401–408.
34.
CohenM. Breast cancer early detection, health beliefs, and cancer worries in randomly selected women with and without a family history of breast cancer. Psychooncology, 2006; 15:873–883.
NormanSA, LocalioAR, ZhouLet al.Validation of self-reported screening mammography histories among women with and without breast cancer. Am J Epidemiol, 2003; 158:264–271.
37.
CaplanLS, McQueenDV, QualtersJR, LeffM, GarrettC, CalongeN. Validity of women's self-reports of cancer screening test utilization in a managed care population. Cancer Epidemiol Biomarkers Prev, 2003; 12:1182–1187.
38.
CalvocoressiL, KaslSV, LeeCH, StolarM, ClausEB, JonesBA. A prospective study of perceived susceptibility to breast cancer and nonadherence to mammography screening guidelines in African American and white women ages 40 to 79 years. Cancer Epidemiol Biomarkers Prev, 2004; 13:2096–2105.
39.
DominickKL, SkinnerCS, BastianLA, BosworthHB, StrigoTS, RimerBK. Provider characteristics and mammography recommendation among women in their 40s and 50s. J Womens Health, 2003; 12:61–71.
40.
ZapkaJG, PuleoE, TaplinSet al.Breast and cervical cancer screening: Clinicians' views on health plan guidelines and implementation efforts. J Natl Cancer Inst Monogr, 2005; 35:46–54.
